Saegis Pharmaceuticals Report issue

For profit Phase 2
Founded: Half Moon Bay CA United States (1999)
Status: Acquired by Lundbeck (2006)

Organization Overview

First Clinical Trial
2004
NCT00093951
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

sgs-742 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1